Literature DB >> 32513017

Minimally invasive oesophagectomy for cancer in patients with HIV/AIDS: considerations and future directions.

S Davakis1, A Syllaios1, A Meropouli1, E Kyros1, I Vagios1, E Mpaili1, E Sdralis2, A Charalabopoulos1,2.   

Abstract

The impact of HIV/AIDS on the treatment of oesophageal neoplasms remains undefined due to a lack of adequate data. We present our experience in treating patients with HIV/AIDS who have oesophageal cancer using minimally invasive techniques and discuss important key factors during perioperative management. Two men with HIV/AIDS underwent minimally invasive oesophagectomies in our department, with adequate clinical and oncological outcomes. Minimally invasive oesophagectomy can be safe and has the well-established benefits of minimally invasive techniques, offering good perioperative results and oncological outcomes in patients with HIV/AIDS. Multimodality therapy is crucial.

Entities:  

Keywords:  AIDS; HIV; Minimally invasive surgery; Oesophageal cancer; Oesophagectomy

Mesh:

Year:  2020        PMID: 32513017      PMCID: PMC7591628          DOI: 10.1308/rcsann.2020.0130

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  3 in total

1.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Authors:  Jacqueline Neuhaus; Brian Angus; Justyna D Kowalska; Alberto La Rosa; Jim Sampson; Deborah Wentworth; Amanda Mocroft
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

2.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

Review 3.  Esophageal disease in the acquired immunodeficiency syndrome: etiology, diagnosis, and management.

Authors:  C M Wilcox
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.